Investing.com - CureVac NV reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
CureVac NV announced earnings per share of €-0.25 on revenue of €11.2M. Analysts polled by Investing.com anticipated EPS of €-0.27 on revenue of €20.33M.
CureVac NV shares are down 76% from the beginning of the year, still down 83.69% from its 52 week high of €50.09 set on November 30, 2021.
CureVac NV follows other major Healthcare sector earnings this month
CureVac NV's report follows an earnings beat by Eli Lilly on November 1, who reported EPS of €1.98 on revenue of €6.94B, compared to forecasts EPS of €1.91 on revenue of €6.91B.
Pfizer had beat expectations on November 1 with third quarter EPS of €1.78 on revenue of €22.6B, compared to forecast for EPS of €1.44 on revenue of €21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar